BiotechTube

SHR2554; Chidamide analog tablets + SHR2554 analog tablets; Chidamide

Phase 3Recruiting
2 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy

Conditions

Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy

Trial Timeline

Feb 5, 2024 → Jul 1, 2026

NCT ID
NCT06122389

About SHR2554; Chidamide analog tablets + SHR2554 analog tablets; Chidamide

SHR2554; Chidamide analog tablets + SHR2554 analog tablets; Chidamide is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06122389. Target conditions include Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy.

What happened to similar drugs?

0 of 9 similar drugs in Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy were approved

Approved (0) Terminated (1) Active (8)
🔄Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
🔄Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclaxAbbViePhase 3
❌Blinatumomab + Standard of Care ChemotherapyAmgenPhase 3
🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3
🔄Axicabtagene Ciloleucel + Cyclophosphamide + Fludarabine + Lenalidomide + Rituximab + Doxorubicin + Vincristine + Prednisone + BendamustineGilead SciencesPhase 3
🔄Odronextamab + Lenalidomide + RituximabRegeneron PharmaceuticalsPhase 3
🔄Zanubrutinib + Rituximab + Lenalidomide + ObinutuzumabBeOne MedicinesPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06122389Phase 3Recruiting

Competing Products

20 competing products in Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy

See all competitors
ProductCompanyStageHype Score
mRNA-2752 + DurvalumabAstraZenecaPhase 1
29
mRNA-2416ModernaPhase 2
0
agenT-797MiNK TherapeuticsPhase 1
19
Valemetostat TosylateDaiichi SankyoPhase 2
39
Eribulin mesylateEisaiPhase 2
35
Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
47
Epcoritamab + Epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone + Venetoclax + Epcoritamab + Lenalidomide + Epcoritamab + Pirtobrutinib + EpcoritamabEli LillyPhase 1/2
36
ISB 1342Glenmark PharmaceuticalsPhase 1
29
Linperlisib ； RituximabJiangsu Hengrui MedicinePhase 1/2
39
Epcoritamab + Epcoritamab, lenalidomide and rituximabAbbViePhase 2
42
EtentamigAbbViePhase 1
33
Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclaxAbbViePhase 3
40
Etentamig + Dexamethasone + Lenalidomide + Pomalidomide + DaratumumabAbbViePhase 1
33
[14C]ABT-199 (GDC-0199)AbbViePhase 1
21
ABT-199 + bortezomib + dexamethasoneAbbViePhase 1
29
Venetoclax + DexamethasoneAbbViePhase 1/2
32
ABBV-453 + Dexamethasone + Daratumumab + LenalidomideAbbViePhase 1
33
AZD4573AstraZenecaPhase 2
35
Moxetumomab PasudotoxAstraZenecaPre-clinical
26
Administration of AZD6738AstraZenecaPhase 1
29